Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasm, Residual 1Lymphoproliferative Disorders 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1Immunoglobulin Light-chain Amyloidosis 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1Amyloidosis 1

Interventions

Cyclophosphamide 444Rituximab 401Etoposide 224Vincristine 215Doxorubicin 201Filgrastim 200Prednisone 176Cytarabine 159Radiotherapy 152fludarabine phosphate 147Methotrexate 137Peripheral Blood Stem Cell Transplantation 129Melphalan 127fludarabine 115Busulfan 99Dexamethasone 93Tacrolimus 75Carmustine 74Granulocyte Colony-Stimulating Factor 73Mycophenolic Acid 71Gemcitabine 66Bortezomib 65Antilymphocyte Serum 65Whole-Body Irradiation 62Cyclosporine 62Bendamustine Hydrochloride 62Lenalidomide 60Ifosfamide 58sargramostim 51Methylprednisolone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lymphoma × Biological Assay × Clear all
NCT06954805 2026-05-27

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Columbia University

Phase 2 Recruiting
30 enrolled
Lymphoid

Lymphoma, Lymphoproliferative Disorders, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡